GAP-43 (neuromodulin) is a protein kinase C substrate that is abundant in developing and regenerating neurons. Thioester-linked palmitoylation at two cysteines near the GAP-43 N terminus has been implicated in directing membrane binding. Here, we use mass spectrometry to examine the stoichiometry of palmitoylation and the molecular identity of the fatty acid(s) attached to GAP-43 in vivo. GAP-43 expressed in either PC12 or COS-1 cells was acetylated at the N-terminal methionine. Approximately 35% of the N-terminal GAP-43 peptides were also modified by palmitate and/or stearate on Cys residues. Interestingly, a variety of acylated species was detected, in which one of the Cys residues was acylated by either palmitate or stearate, or both Cys residues were acylated by palmitates or stearates or a combination of palmitate and stearate. Depalmitoylation of membrane-bound GAP-43 did not release the protein from the membrane, implying that additional forces function to maintain membrane binding. Indeed, mutation of four basic residues within the N-terminal domain of GAP-43 dramatically reduced membrane localization of GAP-43 without affecting palmitoylation. These data reveal the heterogeneous nature of S-acylation in vivo and illustrate the power of mass spectrometry for identification of key regulatory protein modifications.
Covalent modification by acetylation or fatty acylation occurs on a variety of viral and cellular proteins (1) . N-terminal acetylation is one of the most common protein modifications, occurring on ϳ85% of eukaryotic proteins (2) . The amino acid residue adjacent to the amino-terminal methionine residue determines whether the N-terminal methionine is retained or removed before acetylation (2) . Proteins that contain the Nterminal sequence MGXXX(S/T) undergo a different set of modifications. The initiating Met is removed, and myristate is added to the N-terminal glycine. The requirement for glycine at the N terminus is absolute for N-myristoylation to occur.
In contrast to N-terminal acetylation and myristoylation, which occur co-translationally, palmitoylation is a post-translational lipid modification. Nearly all palmitoylated proteins are S-acylated by attachment of palmitate via a thioester linkage to the sulfhydryl group of cysteine. Exceptions include adenylate cyclase toxin from Bordetella pertussis, which is modified by amide-linked palmitoylation on the ⑀-amino group of lysine residues (3) and human sonic hedgehog, which is palmitoylated through an amide linkage to the N-terminal cysteine (4) . Unlike myristoylation, the enzymology of palmitoylation reactions is poorly understood. Palmitoylacyl transferases have not been thoroughly purified and characterized. Moreover, no study has directly examined the nature of thioester-linked palmitoylation in vivo at a molecular level. All of the studies on thioester-linked palmitoylation are based on incorporation of radioactive palmitate. The stoichiometry of palmitoylation as well as the molecular identity of the attached fatty acid moiety (palmitate and/or other fatty acids) have not been directly determined for any S-acylated protein.
To determine which fatty acids are naturally attached via S-acylation, we focused on GAP-43 as a model for a palmitoylated protein. GAP-43 (also known as neuromodulin, B-50, F1, and P57) is enriched in the growth cone membranes of elongating axons (5) (6) (7) (8) (9) and is proposed to function in neuronal plasticity and the regulation of neurotransmitter release (10 -13) . GAP-43 is initially synthesized as a soluble protein, which subsequently passes through the secretory pathway, and becomes membrane-bound post-translationally. Modification of the protein by palmitate at cysteines 3 and 4 has been proposed to be important for membrane binding and for GAP-43 function (14) . Palmitoylation of GAP-43 can occur at the ER 1 -Golgi intermediate compartment and the Golgi apparatus (15) as well as the plasma membrane (14) . Disruption of intracellular transport by brefeldin A inhibits palmitoylation of GAP-43 (16) . Palmitoylation of GAP-43 and neurite outgrowth can also be inhibited by nitric oxide (17) . The N-terminal domain of GAP-43 has been shown to stimulate GTP/GDP exchange on the ␣ subunit of the GTP-binding proteins G o or G i , and palmitoylation of GAP-43 apparently blocks its ability to activate G o (18 -21) .
Although the function of GAP-43 has been extensively studied and linked to palmitoylation, the stoichiometry of GAP-43 palmitoylation is not known. In this study, GAP-43 expressed in PC12 or COS-1 cells was purified and analyzed by mass spectrometry. Use of the sulfhydryl-modifying reagent NEM facilitated the identification of heterogeneously fatty acylated species of GAP-43 in vivo. Here we estimate, based on MALDI-TOF relative ion intensities, that at steady state only 35% of the total GAP-43 population is fatty acylated even though nearly all the GAP-43 is membrane-bound. In addition to palmitoylation, we show that basic amino acid residues near the N terminus of GAP-43 also contribute to the membrane binding of GAP-43.
EXPERIMENTAL PROCEDURES
Materials-Tev protease was purchased from Invitrogen (Carlsbad, CA). Ni-NTA-agarose and anti-PentaHis antibody were obtained from Qiagen (Valencia, CA). Trypsin, N-ethylmaleimide, and defatted BSA were purchased from Sigma Chemical Co. (St. Louis, MO). Na 125 I was from PerkinElmer Life Sciences (Boston, MA). Synthesis and radioiodination of the IC16 (16-iodohexadecanoic acid) fatty acid analog were performed as previously described (22) . Monoclonal anti-GAP-43 antibody (clone 91E12) was purchased from Chemicon (Temecula, CA). Rabbit anti-GAP-43 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Western blots were stained with ECL reagents (Amersham Biosciences, Piscataway, NJ) and were quantitated using the program MacBAS.
Cell Culture and DNA Transfection-PC12 cells (ATCC CRL-1721) were maintained in DMEM-high glucose medium supplemented with 15% horse serum and 2.5% fetal bovine serum. COS-1 cells were grown in DMEM containing 10% fetal bovine serum at 37°C and 5% CO 2 . Cells were transfected using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. The transfection efficiency of PC12 cells was ϳ20%.
Plasmids-The cDNA of human GAP-43 in pBluescript KS ϩ was a generous gift from Dr. Rachael L. Neve (Harvard Medical School and McLean Hospital, Belmont, MA). The GAP-43 coding sequence was subcloned into the EcoRI site of pCMV5 mammalian expression vector with an His tag added to the C terminus. The GAP 16 TevGAPHis 6 , L3GAP 16 TevGAPHis 6 , and L3,4GAP 16 TevGAPHis 6 chimeric constructs were prepared as follows. To facilitate the mass spectrometry analysis, the sequence encoding the seven-amino acid (Glu-Asn-Leu-Tyr-PheGln-Gly) cleavage site for Tev protease was inserted after residue 16 of GAP-43. In the L3GAP 16 TevGAPHis 6 or L3,4GAP 16 TevGAPHis 6 mutants, Cys-3 or both Cys-3 and Cys-4 of GAP-43 were substituted with leucine, respectively. An His tag was attached to the C terminus of GAP-43 to facilitate protein purification. The following primers were used to prepare the L3GAP 16 TevGAPHis 6 construct: 5Ј-CCG GAA TTC  ACC ATG CTG CTC TGT ATG AGA AGA ACC AAA CAG GTT GAA  AAA AAT GAT GAC GAG AAC CTG TAC TTC CAG GGC GAC CAA  AAG ATT GAA CAA GAT GG-3Ј and 5Ј-CGC TCT AGA TTA AAC TCA  GTG GTG GTG GTG GTG GTG ACC GGT GTG GGC ATG TTC TTG  GTC AGC CTC AGG TTC CTC-3Ј. The sense primer, 5Ј-CCG GAA TTC  ACC ATG CTG TGC TGT ATG AGA AGA ACC AAA CAG GTT G-3Ј,  was used to prepare the GAP 16 TevGAPHis 6 construct. For mutation of basic residues at the N terminus of GAP-43, the following sense primer was used for PCR: 5Ј-CCG GAA TTC ACC ATG CTG TGC TGT ATG ATA ATA ACC AAC CAG GTT GAA AAC AAT GAT GAC GAC-3Ј. The N-terminal sequence of all constructs generated by PCR were confirmed by DNA sequencing.
Purification of GAP-43 Chimeric Protein-PC12 or COS-1 cells were transfected with various GAP-43 constructs using LipofectAMINE. Approximately 48 h after transfection, ten plates of cells were harvested and lysed in 5 ml of lysis buffer containing 20 mM Tris (pH 8.0), 500 mM NaCl, 1% Triton X-100, 0.5% CHAPS, 5 mM imidazole, and 1 mM phenylmethylsulfonyl fluoride. After centrifugation at 100,000 ϫ g for 15 min, the supernatant was applied to a column that contained 1 ml of suspension of Ni-NTAagarose and was previously equilibrated with lysis buffer. The column was extensively washed with buffer containing 20 mM Tris (pH 8.0 or 7.0), 500 mM NaCl, and 20 mM imidazole. Samples were eluted with 2 ml of elution buffer containing 20 mM Tris (pH 8.0 or 7.0) and 0.2 M imidazole. The protein was concentrated using an Amicon filter. Protein digestion with Tev protease was carried out according to the manufacturer's instructions and was monitored by Western blotting and Coomassie Blue staining.
Digestion of Purified GAP-43-Affinity-isolated GAP-43 proteins (10 g at a concentration of ϳ1 mg/ml), with wild type or mutant Nterminal amino acid sequences, were digested at 30°C overnight with 1 g of trypsin or 10 units of Tev protease in 20 mM Tris (pH 7.0 or 8.0). At the end of the digestion, Triton X-100 was added to a final concentration of 0.1%. Mass Spectrometry-Molecular masses of digested peptides were determined at the New York University Protein Analysis Facility. The digestion mixture (0.5 l) was mixed with 0.5 l of 10 mg/ml cyano-4-hydroxycinnamic acid (Sigma-Aldrich) in 50% acetonitrile and 0.1% trifluoroacetic acid, air-dried, and analyzed on a Micromass TofSpec-2E (MALDI-TOF) mass spectrometer in reflection mode using standard instrument settings. Internal and/or external calibration was carried out using synthetic A␤ 1-42 (average mass ϭ 4513.1 Da), angiotensin I (average mass ϭ 1296.5 Da), and insulin (average mass ϭ 5733.5 Da).
Positive ion nanoelectrospray ionization mass and tandem mass spectra were acquired on a Micromass (Manchester, UK) Q-TOF instrument equipped with a Z-spray nanoelectrospray ionization interface. Samples in 50% acetonitrile/1% acetic acid were sprayed from goldcoated "medium length" borosilicate capillaries (Protana, Odense, Denmark) as described previously (23) . In some cases samples were desalted using Zip-Tip TM C 18 micro-columns (Millipore) before Q-TOF analysis. The deconvoluted MS/MS spectra were manually interpreted with the help of MassLynx software.
Hydroxylamine Treatment of Labeled Membranes-COS-1 cells transfected with wild type GAP-43 were labeled for 4 h with 16-[
125 I]iodopalmitate in DMEM containing 2% dialyzed fetal bovine serum, 0.25% defatted BSA at 37°C. Cells were harvested and resuspended in hypotonic buffer, lysed by homogenization with 30 strokes of a Dounce homogenizer, and centrifuged at 100,000 ϫ g for 1 h to obtain a cytosolic fraction (S) and a membrane fraction (P). For treatment with hydroxylamine, the membrane fraction was resuspended in either 1 M Tris (pH 7.0) or 1 M hydroxylamine (pH 7.0) and incubated overnight at 4°C. After centrifugation at 100,000 ϫ g for 15 min to obtain a soluble fraction (SЈ), the pellet was dissolved in radioimmune precipitation assay buffer and clarified by centrifugation to generate the PЈ fraction. Each fraction was incubated with Ni-NTA-agarose to isolate GAP-43. Purified GAP-43 was analyzed by SDS-PAGE, followed by phosphorimaging or Western blotting with rabbit anti-GAP-43 antibody.
Immunofluorescence Staining-PC12 cells were plated onto poly-Llysine-coated glass coverslips overnight and were transfected with either wild type GAP-43 or mutant GAP-43 for 48 h. PC12 cells were washed with PBS and fixed in 3.7% paraformaldehyde for 15 min, washed with 100 mM glycine in Tris buffered saline (10 mM Tris (pH 7.5), 150 mM NaCl) for 10 min to quench the aldehyde, and then washed with PBS. Cells were permeabilized with 0.2% Triton X-100 in PBS for 5 min. Following washing with PBS, cells were blocked with 4% normal donkey serum (Jackson ImmunoResearch) in PBS for 1 h and then incubated for 1.5 h with anti-PentaHis antibody at 1:250 dilution in 4% donkey serum. After extensive washing with PBS, cells were incubated for 1 h with Alexa-Green-conjugated goat anti-mouse secondary antibodies (Molecular Probes) at a dilution of 1:500 in 4% donkey serum. After washing with PBS, cell nuclei were stained for 5 min with 2 ml of Hoechst 33258 in PBS at a final concentration of 50 g/ml. After extensively washing with PBS, coverslips were mounted on slides using Prolong Antifade mounting media (Molecular Probes). The cells were viewed using a Zeiss LSM510 confocal microscope.
RESULTS

Analysis of Tryptic Digests of GAP-43-GAP-43 has been
shown to be palmitoylated based on incorporation of radiolabeled palmitate. Mutation of Cys-3 and Cys-4 blocks radiolabel incorporation, suggesting that these residues are the sites of modification (27) . To study the nature of thioester-linked palmitoylation on a molecular level, we attempted to isolate the N-terminal palmitoylated peptide of GAP-43. Wild type GAP-43 tagged with 6 histidines at the C terminus was expressed in PC12 cells, purified through a Ni-NTA-agarose affinity column, and digested with trypsin. The resulting tryptic peptides were analyzed by MALDI-TOF mass spectrometry. The calculated monoisotopic mass of an N-acetylated peptide derived from tryptic cleavage of the first six amino acids is 797.31. As depicted in Fig. 1A , a tryptic peptide of m/z 796.25 (or mass 795.25) was clearly observed, which is 2 Da less than the calculated mass for the N-acylated peptide. This suggests that an intramolecular disulfide bond formed between Cys-3 and Cys-4. The nature of the intramolecular disulfide bond was confirmed by Q-TOF MS/MS sequence analysis as shown in Fig. 1B . Surprisingly, the analysis indicated that the vast majority of N-terminal peptides were not palmitoylated, although there may be a small number of fatty acylated peptides observed upon close inspection of the spectrum (Fig. 1A, inset) . This result is consistent with a previous mass spectrometric analysis of GAP-43 isolated from calf brain, which reported that cysteine residues at the N terminus of GAP-43 are not palmitoylated but form an intramolecular disulfide bond (24) .
Analysis of GAP-43 Labeled with a Radioactive Palmitate Analog-We next investigated several possibilities that might explain why so few palmitoylated peptides were detected in our initial MALDI-TOF analysis of GAP-43 tryptic peptides. One possible explanation is that the palmitoylated species was lost during protein purification due to its hydrophobicity. Alternatively, the stoichiometry of palmitoylation of GAP-43 in these cells might be low. To explore these possibilities, we engineered a recombinant GAP-43 protein by inserting a specific Tev protease cleavage site after the N-terminal 16 residues of GAP-43 and a hexa-histidine tag at the C terminus to facilitate purification ( Fig. 2A) . Theoretically, only two peptides should be generated after the GAP-43 protein is cleaved with Tev protease. Thus, the background would be greatly reduced and the signal from the N-terminal peptide should be dramatically increased.
We first examined the palmitoylation status of GAP-43. COS-1 cells expressing wild type GAP-43 were incubated with [ 125 I]IC16, a radioactive palmitate analog (25, 26) . GAP-43 was purified via Ni-NTA-agarose affinity column chromatography. Each purification step was monitored by Western blotting to ensure that the majority of GAP-43 (Ͼ80%) was solubilized and recovered from the column (Fig. 2B) . Purified proteins were concentrated to ϳ1 mg/ml and digested with Tev protease. The efficiency of digestion was monitored by Western blotting and Coomassie Blue staining (Fig. 2, C and E) . As expected, GAP-43 incorporated the labeled palmitate analog. The level of label on GAP-43 was diminished after the protein was cleaved with Tev protease (Fig. 2D) , suggesting that the labeled palmitate analog was incorporated at the N terminus of GAP-43.
To minimize the loss of hydrophobic acylated peptides, the digestion mixture was directly analyzed by mass spectrometry without passage through reverse phase column purification. As shown in Fig. 3 , the observed monoisotopic mass of the Nterminal peptide of wild type GAP-43 was 2803.24 (i.e. m/z of M ϩ H ϩ is 2804.24). With N-terminal acetylation taken into account, the calculated monoisotopic mass of the N-terminal peptide is 2805.27. The 2-Da difference between the calculated and the observed mass is indicative of an intramolecular disulfide formed between Cys-3 and Cys-4 (Fig. 3A) . Indeed, when the sample was treated with 1% mercaptoethanol for 1 h at room temperature, the mass of the acetylated N-terminal peptide regained 2 Da, confirming the formation of an intramolecular disulfide (Fig. 3B) .
A previous study showed that the L3 mutant of GAP-43, in which Cys-3 is substituted with Leu, incorporates [ 3 H]palmitate to 75% of the level of the wild type protein (27) . When the L3GAP-43 expressed in COS-1 cells was purified, digested with Tev protease, and analyzed by mass spectrometry, a peptide of monoisotopic m/z ϭ 2815.93 was observed, consistent with an acetylated but not palmitoylated N terminus. An acetylated N terminus was also detected when both Cys-3 and Cys-4 were substituted with Leu (data not shown). No palmitoylated peptides were detected in either wild type or L3 mutant samples. Because the labeled palmitate analog appeared with the purified proteins and Western blot experiments showed that the majority of GAP-43 proteins were recovered, this suggested that only a small percentage of GAP-43 protein was modified by palmitate.
Heterogeneous S-acylation of GAP-43-An alternative possibility was that the cysteine residues of GAP-43 were being oxidized during protein purification, resulting in the formation of an intramolecular disulfide bond. To prevent nucleophilic attack on adjacent modified cysteines, we utilized N-ethylmaleimide (NEM), a small membrane-permeable reagent that can covalently modify free sulfhydryl groups. To determine the percentage of cysteine residues at the N terminus of GAP-43 that exist as free sulfhydryl groups in vivo, COS-1 cells expressing wild type GAP-43 were pretreated with NEM. The cells were lysed under N 2 in hypotonic buffer containing NEM, so as to minimize the oxidation of sulfhydryl groups by air. Detergent was then added to solubilize the membranes, and GAP-43 was purified via Ni-NTA affinity chromatography. The purified protein was digested with Tev protease and analyzed by mass spectrometry. As depicted in Fig. 4 (Table I) . These NEM-modified peptides were likely derived from peptides with cysteines in the reduced form. Based on the data in Table I , about 90% of the unacylated N-terminal peptides are in the reduced state in vivo, presumably due to the high cytoplasmic concentration of reduced glutathione.
Populations of fatty acylated GAP-43 peptides were also detected. The calculated monoisotopic m/z of a protonated monoacylated peptide modified by one palmitate is 3044.50. As depicted in Fig. 4 , a peptide of m/z ϭ 3044.53 was observed, corresponding to a singly palmitoylated N-terminal peptide of GAP-43. Interestingly, a peptide of m/z ϭ 3072.51 was also apparent. The mass of this peptide is 28 daltons more than the palmitoylated peptide, suggesting that some of the N-terminal peptides of GAP-43 were acylated by stearate. Q-TOF MS/MS experiments confirmed this peptide contained the N-terminal peptide sequence but the complicated MS/MS fragmentation pattern suggested more than one peptide within the 3-Da window used for selecting the triply charged precursor ion. Indeed, the peak at monoisotopic m/z 3070.58 suggests the possibility that some of the N-terminal peptides may be acylated by oleate. The peptide of m/z ϭ 3169.57 represented a monoacylated N-terminal sequence of GAP-43 modified by palmitate with an additional modification by one NEM, whereas the peptide of m/z ϭ 3197.59 represented a species where one cysteine was modified by stearate and the other cysteine was modified by one molecule of NEM. Again, the peak at m/z 3195.6 in addition to the peak at 3197.59 indicates these peptides were modified by either stearate or oleate in addition to the NEM. With FIG. 1. Tryptic digestion of GAP-43 . A, wild type GAP-43 expressed in PC12 cells was isolated via Ni-NTA-agarose, digested with trypsin, and analyzed by MALDI-TOF mass spectrometry. B, analysis of the amino acid sequence of the N-terminal tryptic peptide by nanoelectrospray Q-TOF tandem mass spectrometry.
NEM-modified monoacylated peptides taken into account, ϳ26.8% of the N-terminal peptides were monoacylated by either palmitate or stearate (Table I) .
The calculated mass of a dually palmitoylated peptide is 3281.73 (i.e. m/z 3282.73). As depicted in Fig. 4 , a peptide of m/z ϭ 3282.73 was clearly apparent in addition to lighter peaks corresponding to peptides modified by unsaturated fatty acyl groups. Interestingly, a peptide of m/z ϭ 3310.74 was also observed, consistent with the expected mass for modification by both palmitate and stearate. Again, the inset to Fig. 4 clearly indicates peaks at m/z 3308.74 and 3306.92 corresponding to peptides modified by one or two unsaturated acyl groups. The dually acylated peptides represented only 8.6% of the total (Table I) . Taken together, these results indicate that only about one-third of the total GAP-43 population is monoacylated or dually acylated by palmitate and/or stearate at steady state in vivo.
Depalmitoylation Does Not Release GAP-43 from the Membrane-Because the majority of GAP-43 protein is membranebound, but not palmitoylated at steady state, other forces may be sufficient to maintain stable membrane association in the absence of palmitate. To test this, COS-1 cells expressing wild type GAP-43 were incubated with the IC16, a radioactive palmitate analog. Cells were then lysed in hypotonic buffer, and membrane pellets were obtained after centrifugation at 100,000 ϫ g for 1 h. Half of the pellet sample was resuspended in 1 M Tris-HCl (pH 7.0) overnight, and the other half was resuspended in 1 M hydroxylamine (pH 7.0). Soluble and membrane fractions were obtained by centrifugation. The distribution of GAP-43 was analyzed by immunoblotting with anti-GAP-43 antibody, and labeled GAP-43 was detected by phosphorimaging. As depicted in Fig. 5A , more than 70% of the total GAP-43 was present in the membrane fraction. Almost all of the labeled GAP-43 was located in the membrane pellet. Treatment of labeled membranes with Tris removed about 35% of the total GAP-43 from the membranes but did not remove any incorporated label from GAP-43. In contrast, treatment of labeled membranes with hydroxylamine resulted in release of about 30% of the total GAP-43 from the membrane, but more than 95% of the labeled palmitate analog was removed from GAP-43 (Fig. 5B) . This result suggests that palmitoylation might not be required to maintain stable association of GAP-43 with the membrane, and that other factors might contribute to membrane binding of GAP-43.
Replacement of Basic Residues at the N Terminus of GAP-43 Resulted in Decreased Membrane
Localization-A previous mutagenesis study on GAP-43 indicated that two adjacent cysteines as well as basic residues near the N terminus of GAP-43 are required for axonal targeting (28) . We therefore examined whether the basic residues near the N terminus of GAP-43 contribute to fatty acylation and membrane binding of GAP-43. A recombinant GAP-43 protein was designed with arginines 6 and 7 substituted with isoleucines and lysines 9 and13 mutated to asparagines, denoted R 6,7 I-K 9,13 N. A hexa-His tag was appended to the C terminus. PC12 cells transiently expressing wild type and mutant GAP-43 were fixed, incubated with antiHis tag antibody, and then stained with Alexa-Green-conjugated goat anti-mouse secondary antibody. Nuclei were stained with Hoechst dye. The subcellular localization of wild type and mutant GAP-43 was examined by confocal microscopy. As depicted in Fig. 6A , PC12 cells transfected with wild type GAP-43 exhibited distinct plasma membrane fluorescence. The staining pattern of the R 6,7 I-K 9,13 N mutant GAP-43 appeared more diffuse, with immunoreactivity apparently present in the cytosol.
To resolve the differences between wt and mutant GAP-43 constructs more precisely, the localization of GAP-43 was also examined using biochemical methods. Transfected PC12 cells or COS-1 cells were fractionated into soluble (S100) and membrane (P100) fractions. Each fraction was incubated with Ni-NTA-agarose to isolate wild type and mutant proteins. The distribution of total wild type and R 6,7 I-K 9,13 N mutant GAP-43 proteins was analyzed by Western blotting with anti-GAP-43 antibody. As depicted in Fig. 6B , Ͼ90% of the wild type GAP-43 in PC12 cells was recovered from the membrane fraction. In contrast, Ͻ25% of the R 6,7 I-K 9,13 N mutant GAP-43 was located in the membrane fraction, indicating that N-terminal basic residues of GAP-43 play an important role in membrane binding.
We next determined whether mutation of the basic residues altered the ability of GAP-43 to incorporate labeled palmitate. Cells expressing wild type and mutant GAP-43 were preincubated with the IC16 radioactive palmitate analog, lysed, and fractionated into soluble and membrane fractions. The distribution of labeled proteins was analyzed by phosphorimaging. As depicted in Fig. 7 , R 6,7 I-K 9,13 N mutant GAP-43 incorporated the labeled palmitate analog as well as wild type GAP-43, although the expression level of mutant GAP-43 was slightly higher than the wild type GAP-43. As expected, over 90% of the labeled wild type GAP-43 was localized to the membrane fraction. All of the IC16-labeled mutant GAP-43 was present in the membrane fraction. These data suggest that mutation of the N-terminal basic residues of GAP-43 decreased the capability of GAP-43 to bind to membranes without affecting the level of fatty acylation.
DISCUSSION
Heterogeneous S-Acylation of GAP-43-Previous studies of thioester-linked palmitoylation have been entirely based on incorporation of radioactive palmitate into target proteins. However, this technique does not allow one to determine the stoichiometry of palmitoylation in vivo. Moreover, thioesterlinked palmitoylation is a reversible reaction that is susceptible to alkali hydrolysis, which makes purification of palmitoylated proteins difficult. We, therefore, have directly examined the nature of thioester-linked palmitoylation in vivo using mass spectrometry.
GAP-43/neuromodulin was chosen as a model protein for these studies because it has been reported to undergo multiple modifications, including palmitoylation and phosphorylation (29, 30) . A previous study of GAP-43 isolated from calf brain revealed that the N terminus of GAP-43 is acetylated, and that cysteines 3 and 4 form an intramolecular disulfide bridge; no palmitoylated peptides were detected (24) . We obtained similar results when GAP-43 was expressed in PC12 cells or COS-1 cells. However, we reasoned that formation of an intramolecular disulfide bond was due to oxidation of free sulfhydryl groups during protein isolation. This explanation would be consistent with the finding that iodoacetamide labeling of growth cone membrane proteins failed to reveal a pool of GAP-43 molecules with free cysteine thiols (14) .
There are several reasons that might explain the initial failure to detect an N-terminal palmitoylated GAP-43 peptide by mass spectrometry. It is possible that the stoichiometry of GAP-43 palmitoylation is not high. In addition, the major peptide representing the oxidized form of GAP-43 might suppress the signal from the palmitoylated species of GAP-43. Alternatively, the palmitate moiety might have been lost upon cell lysis and/or purification. Because monoacylated peptides of GAP-43 are predominant among the acylated species (Table I) , the free sulfhydryl group could act as a nucleophile and attack the neighboring thioester bond, resulting in removal of palmitate and formation of an intramolecular disulfide. The use of NEM allowed us to identify the molecular nature of the modification(s) of GAP-43 cysteine residues and to use mass spectrometry to estimate the stoichiometry of palmitoylation occurring in vivo. NEM is membrane-permeable and can covalently react with free sulfhydryl groups in vivo. Using NEM, we determined that ϳ35% of the N-terminal GAP-43 peptides that we recovered are monoacylated or dually acylated by palmitate and/or stearate. It is unlikely that the low stoichiometry of palmitoylation of GAP-43 is due to the loss of palmitate during protein purification, because free sulfhydryl groups were covalently modified by NEM in vivo. With NEMmodified peptides taken into account, ϳ90% of the unacylated Cys residues exist as free sulfhydryl groups in vivo, presumably due to the high concentration of reduced glutathione. The availability of free sulfhydryl groups on cysteines 3 and 4 allows GAP-43 to be additionally modified by ADP-ribosylation (31) and glutathiolation by glutathione disulfide S-oxide (32) .
Our quantitation of the prevalence of the various GAP-43 peptide species was based on the relative ion intensities in the MALDI-TOF mass spectrometry analysis. However, it is important to note that these numbers should be viewed as crude estimates for the following reasons. First, the MALDI-TOF ion intensities (peak heights) can be influenced by multiple factors, including peptide composition. Second, we cannot distinguish between a peptide modified with two mono-unsaturated fatty acids versus a peptide containing one di-unsaturated fatty acid and one saturated fatty acid, because the molecular masses of the two species are the same (however, we did not detect any peptides modified with two di-unsaturated fatty acids). Third, overexpression of GAP-43 and/or the use of lipophilic transfection reagents may influence the relative abundance of the fatty acylated species in the cell. Despite these caveats, this is the first study to characterize and quantitate the molecular nature of thioester-linked fatty acylation on a specific cellular protein in vivo.
For the monoacylated peptides, we did not determine whether palmitoylation occurred on Cys-3 or Cys-4, because both peptides have the same molecular mass. However, a previous report showed that the level of [ 3 H]palmitate incorporation into the L3 mutant of GAP-43 was 75% of that of wild type GAP-43. This implies that palmitoylation occurs preferentially on Cys-4 and that palmitoylation of Cys-3 might be dependent on the presence of Cys-4. Dual fatty acylation of GAP-43 may therefore be a sequential process.
The finding that GAP-43 can be heterogeneously fatty acylated is consistent with studies of other S-acylated proteins. For example, previous analysis of S-linked fatty acids released from total heart and liver proteins revealed the presence of 14:0, 18:0, 18:1, and18:2 fatty acids in addition to 16:0 (33). We recently reported that the Src family member Fyn could be heterogenously acylated with radioactive stearate, oleate, and arachidonate (34) . However, this is the first study to use mass spectrometry as a tool to identify the spectrum of fatty acids that are naturally attached to a specific protein in vivo. As ]IC16 and subjected to differential centrifugation to obtain soluble (S) and membrane (P) fractions. Pellets were solubilized as described under "Experimental Procedures." Fractions containing equivalent volumes of material were incubated with Ni-NTA-agarose to isolate GAP-43, followed by Western blotting and phosphorimaging. B, the membrane fraction was resuspended in either 1 M Tris buffer (pH 7.0) or 1 M hydroxylamine (pH 7.0) (HA) overnight at 4°C, and the suspension was then centrifuged to obtain soluble (SЈ) and pellet (PЈ) fractions. Pellets were solubilized and GAP-43 was isolated, followed by analysis by Western blotting and phosphorimaging. Experiments were repeated three times with similar results.
FIG. 6. Subcellular localization of wild type and mutant GAP-43 in PC12 cells by confocal imaging.
A, PC12 cells expressing wild type and mutant GAP-43 were stained with an anti-His tag antibody and Alexa-Green-conjugated goat anti-mouse secondary antibody. Nuclei were stained with Hoechst (DAPI). B, PC12 cells expressing wild type and mutant GAP-43 were fractionated into soluble (S100) and membrane (P100) fractions. GAP-43 was isolated via Ni-NTA-agarose chromatography, followed by SDS-PAGE and Western blotting with anti-GAP-43 antibody.
FIG. 7.
Mutation of N-terminal basic residues reduced membrane localization of GAP-43. COS-1 cells expressing wild type or R 6,7 I-K 9,13 N mutant GAP-43 were radiolabeled with [ 125 I]IC16 and then were either lysed directly in lysis buffer or fractionated into soluble (S) and membrane (P) fractions. Lysates or fractions were incubated with Ni-NTA to isolate GAP-43, as described under "Experimental Procedures," and then analyzed by SDS-PAGE, Western blotting, and phosphorimaging. Experiments were performed four times with similar results. depicted in Fig. 4 , we demonstrate that GAP-43 can be monoacylated with palmitate or stearate and dually acylated with palmitates or a combination of palmitate and stearate. In the future, the combination of NEM treatment and mass spectrometry can be exploited to identify the molecular nature of the fatty acid modifications of other S-acylated proteins.
Basic Residues at the N Terminus of GAP-43 Also Contribute to Membrane Binding-The finding that mutation of Cys-3 and Cys-4 leads to decreased palmitate incorporation and decreased membrane binding has led other investigators to conclude that palmitoylation of the N-terminal domain of GAP-43 is necessary for membrane association (27) . Here we show that, although GAP-43 is mostly membrane-bound, only one-third of the protein is fatty acylated in vivo at steady state. In addition, treatment of membrane-bound GAP-43 with hydroxylamine to remove Cys-linked acyl groups does not release GAP-43 from the membrane (Fig. 5) . This result is in agreement with a previous finding for SNAP-25 (16) and suggests that palmitoylation is not required to maintain stable association of these proteins with membranes. The loss of membrane binding that occurred upon mutation of Cys-3 and -4 may reflect a requirement for the presence of these two cysteine residues per se, rather than a need for palmitoylation.
To determine what other factors might contribute to membrane binding of GAP-43, four basic residues at the N terminus of GAP-43 were substituted with neutral residues. The rationale for this experiment was based on the ability of "myristate plus basic" motifs to promote membrane binding of other fatty acylated proteins (e.g. Src, HIV-1 Gag, myristoylated alaninerich C kinase substrate) (1) . As shown in Fig. 7 , mutation of the basic residues of GAP-43 dramatically reduced membrane localization of GAP-43 but had no effect on palmitoylation. It is therefore possible that electrostatic interaction between basic residues and acidic phospholipids might contribute to membrane binding of GAP-43 via a "fatty acid plus basic" motif. Alternatively, the cysteines and/or basic residues in the Nterminal region of GAP-43 may be involved in protein-protein interactions at the membrane.
It is also likely that palmitoylation and/or the basic residues are involved in membrane targeting. GAP-43 as well as a related palmitoylated protein, SNAP-25, are transported to the plasma membrane via the secretory pathway (16) . Palmitoylation of these proteins likely occurs in the ER-Golgi intermediate compartment or trans Golgi network (14, 15, 35) . Palmitoylated proteins could then be sorted into trafficking vesicles that are targeted to specific membrane destinations. For example, palmitoylated GAP-43 is associated with plasma membrane rafts (36) . Moreover, a recent study demonstrated that the palmitoylation motif of GAP-43 as well as two basic residues (Arg-6 and Arg-7) are involved in polarized trafficking of GAP-43, by serving to target the protein to axonal membranes (28) .
Future research will be directed toward elucidating the role of the N-terminal motif of GAP-43 and its covalent modification in membrane binding versus membrane targeting.
